Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348992 | 0.97 | RAD52 (0.47) | RAD52KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3321877 | 0.95 | — | — | |
| SCHEMBL3314879 | 0.89 | — | — | |
| SCHEMBL3298507 | 0.86 | RAD52 (0.52) | RAD52KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27461328 | 0.85 | SIGMAR1 (0.52) | KDM4ESIGMAR1CXCR4CXCL12ALDH1A1 | |
| SCHEMBL22175381 | 0.83 | SIGMAR1 (0.55) | KDM4ESIGMAR1CXCR4CXCL12ALDH1A1 | |
| SCHEMBL681346 | 0.83 | CXCR4 (0.52) | RAD52KDM4ESIGMAR1CXCR4CXCL12 | |
| SCHEMBL455085 | 0.83 | RAD52 (0.56) | RAD52KDM4ECXCR4CXCL12ALDH1A1 | |
| SCHEMBL1779849 | 0.83 | RAD52 (0.56) | RAD52KDM4ECXCR4CXCL12ALDH1A1 | |
| SCHEMBL25975593 | 0.82 | CARM1 (0.35) | RAD52SIGMAR1CXCR4CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | RAD52 4482/4885KDM4E 4303/4885CYP1A2 2749/4885 |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPV1 | RAD52 4668/4885KDM4E 4283/4885CYP1A2 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.